pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 27·1 min read
save

Experts say Covid risk has faded, but boosters still advised for vulnerable groups

Apr 27, 2026·read at STAT ↗Neutral

Health journalist Helen Branswell reflects on how Covid-19, once the dominant global threat, has receded in public consciousness. Six years after the 2020 lockdowns, mask-wearing and social distancing are largely memories, and the virus no longer dominates headlines.

STAT surveyed a range of infectious-disease experts to gauge current risk assessments. Most said the immediate danger of SARS-CoV-2 has diminished, noting that recent winter illness spikes were driven by influenza rather than Covid.

Nevertheless, the experts cautioned that certain groups-older adults, immunocompromised patients and those with chronic conditions-remain at higher risk. They continue to recommend Covid booster shots for these vulnerable populations.

Overall, the consensus is that Covid has shifted from a pandemic emergency to a manageable endemic disease, but surveillance and targeted vaccination will persist as part of public-health strategy.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “What happened to Covid?”

read at STAT ↗
2,394 words · retrieved Apr 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Emory University2PFIZERUniversity of Iowa
drugs
AmbienOzempicWegovy
topics
Vaccines8Vaccine6Infectious Disease5Immunology4Pulmonology4AdComCardiologyPsychiatry & CNS

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 4d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • 5d agoSTAT+: FDA adcomm members’ ties to industry under scrutinySTAT
  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT